Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A New Hope in the Fight Against Triple-Negative Breast Cancer

Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors: A New Hope in the Fight Against Triple-Negative Breast Cancer

In the rapidly evolving field of oncology, breakthroughs are continuously shaping the way we approach the most challenging cancers. One such breakthrough is the potential of Poly (Adenosine Diphosphate-Ribose) Polymerase inhibitors (PARPi) in the treatment of triple-negative breast cancer (TNBC), a particularly aggressive and hard-to-treat subtype of breast cancer. Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College has authored a study published in Medicinal Research Reviews, a journal with an impact factor of 10.9. The study, titled “Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous recombination repair deficiency,” explores the potential of novel therapies known as PARP inhibitors. It specifically examines how these therapies can target the unique vulnerabilities of triple-negative breast cancer tumors with homolo
SIFIC 2024 | Dr. Xiaodong Gao: Integrating Global Expertise to Explore New Strategies for Infection Control in China

SIFIC 2024 | Dr. Xiaodong Gao: Integrating Global Expertise to Explore New Strategies for Infection Control in China

The 20th Shanghai International Forum for Infection Control (SIFIC), in conjunction with the 8th Oriental Forum on Challenging Infectious Diseases (OFCID) and the Academic Corference of Global Chinese Association of Clinical Microbiology & Infectious Diseases , were held at the Shanghai International Convention Center from July 25-27, 2024. At this academic event, Dr. Xiaodong Gao from Zhongshan Hospital  delivered an in-depth lecture on key topics such as hospital infection assessment, infection control management, hand hygiene practices, and the WHO Global Action Plan on Infection Prevention and Control. In an interview with Infectious Diseases Frontier, Dr.  Gao not only reviewed the founding vision of SIFIC but also provided an in-depth analysis of strategies for infection prevention and control (IPC), the details of hand hygiene management, and how multidisciplinary collaboration can strengthen infection control efforts.
AIDS Hot Topic Commentary | Dr. Linghua Li’s Team: Successful Construction of a Chronic SHIV/HBV Co-infection Model in Rhesus Macaques

AIDS Hot Topic Commentary | Dr. Linghua Li’s Team: Successful Construction of a Chronic SHIV/HBV Co-infection Model in Rhesus Macaques

Due to similar transmission routes, approximately 20% of people living with HIV (PLWH) are co-infected with hepatitis B virus (HBV). For decades, rhesus macaques (RMs) have served as a model for HIV research, but they have never been used to study HIV/HBV co-infection. At the AIDS 2024 conference, a research team from Oregon Health & Science University presented an oral report on their successful construction of an RM model co-infected with SHIVDH12 Clone 7 and HBV genotype D. A key advantage of this animal model is the ability to obtain longitudinal biopsies and dynamically monitor changes in immune cell phenotypes and ALT levels, providing better insights into the pathogenesis of co-infection. This article invites Dr. Linghua Li’s team from Guangzhou Eighth People's Hospital, Guangzhou Medical University to delve into this study and interpret the deeper significance behind these research findings.
Dr. Jidong Jia: China’s New Guidelines for Chronic Hepatitis B Mark a Transition from Following to Leading

Dr. Jidong Jia: China’s New Guidelines for Chronic Hepatitis B Mark a Transition from Following to Leading

From July 25 to 28, 2024, the Combined GIHep & SHC 2024 was held in Singapore. Dr. Jidong Jia from Beijing Friendship Hospital, Capital Medical University, participated in the Chronic Hepatitis B symposium and delivered a remarkable presentation on the new Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition) (hereinafter referred to as the "New Guidelines"). Hepatology Digest conducted an exclusive interview with Professor Jia to discuss the highlights of his presentation.
AIDS Interview丨Inhibiting HIV Transcription to Achieve Maximum Disease Remission

AIDS Interview丨Inhibiting HIV Transcription to Achieve Maximum Disease Remission

At the AIDS 2024 conference, Dr. Melanie Ott from the University of California, San Francisco, delivered a special report titled "The Sound of Silence: Tackling HIV Transcription to Achieve Remission," which garnered widespread attention. Following the conference, Infectious Diseases Frontier conducted an in-depth interview with Dr.  Ott, where she elaborated on the significance of HIV transcription mechanisms in regulating viral reservoirs, which play a crucial role in the rebound of the virus after treatment interruption. Professor Ott highlighted that a novel strategy involving the use of transcription inhibitors in combination with existing antiretroviral therapy (ART) could potentially suppress transcriptional activity in reservoir cells, thereby delaying viral rebound and reducing immune activation, bringing new hope and breakthroughs to the field of HIV treatment.
Dr. Yingli He: Building a Defense Against Liver Cancer—Antiviral Treatment Strategies for CHB Patients in the Context of Comprehensive Liver Cancer

Dr. Yingli He: Building a Defense Against Liver Cancer—Antiviral Treatment Strategies for CHB Patients in the Context of Comprehensive Liver Cancer

Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) presents a significant public health challenge in China, with the majority of HCC patients being diagnosed at an advanced stage. Postoperative survival rates for HBV-related HCC patients are often poor. Therefore, the prevention and treatment of HBV-related HCC urgently require comprehensive management. China has achieved remarkable success in primary prevention of hepatitis B. Regular screening and early treatment in high-risk populations are crucial to reducing HCC mortality. Antiviral treatment is an important measure for secondary and tertiary prevention of HBV-related HCC. At the 2024 World Hepatitis Day and the Elimination of Hepatitis Harm Action Conference, Dr. Yingli He from the First Affiliated Hospital of Xi'an Jiaotong University shared insights into antiviral treatment strategies for chronic hepatitis B (CHB) patients from the perspective of comprehensive liver cancer management.
How Should Chinese Women Approach Breast Cancer Screening?

How Should Chinese Women Approach Breast Cancer Screening?

Breast cancer has now become the most common malignant tumor worldwide and is one of the most prevalent cancers among Chinese women, posing a serious threat to their physical and mental health. While significant progress has been made in the treatment and drug development for breast cancer, providing more targeted treatment options for different types of patients and improving survival rates and quality of life, our ultimate goal is to reduce the incidence of breast cancer through screening and prevention. Early detection is crucial for improving treatment outcomes and extending survival times. This article discusses breast cancer screening and how high-risk groups can reduce their risk of developing breast cancer.
In-Depth Analysis | Dr. Yuhua Song & Dr. Jing Yao: Treatment Options for HR+/HER2- Breast Cancer Patients After CDK4/6i Progression

In-Depth Analysis | Dr. Yuhua Song & Dr. Jing Yao: Treatment Options for HR+/HER2- Breast Cancer Patients After CDK4/6i Progression

After CDK4/6i treatment failure in HR+/HER2- breast cancer patients, do you lean more towards a PI3K inhibitor or an AKT inhibitor? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Yuhua Song from The Affiliated Hospital of Qingdao University and Dr. Jing Yao from Union Hospital Affiliated with Huazhong University of Science and Technology each presented their views. Professor Song expressed a preference for PI3K inhibitors, while Professor Yao favored AKT inhibitors. Following the session, Cancer Outlook invited both experts to elaborate on their perspectives.
In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

In-Depth Analysis | Dr. Xuening Ji & Dr. Chunfang Hao: Treatment Options After TKI Therapy Failure in HER2-Positive Breast Cancer

After the failure of TKI therapy in HER2-positive breast cancer, would you prefer an "ADC" or "HP+" regimen? At the Northern Salon of the 2024 Summer Breast Cancer Forum, during the "In-Depth Analysis" segment, Dr. Xuening Ji from Affiliated Zhongshan Hospital of Dalian University and Dr. Chunfang Hao from Tianjin Cancer Hospital shared their perspectives. Professor Ji advocated for the ADC approach, while Professor Hao supported the "HP+" regimen. Following the session Oncology frontier  invited both experts to elaborate on their viewpoints.
Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

Dr. Jidong Jia: Progress and Challenges in the Prevention and Treatment of Hepatitis B in China

China has historically been a high-prevalence area for Hepatitis B virus (HBV) infection, with a hepatitis B surface antigen (HBsAg) prevalence rate of 9.7% in 1992. Comprehensive strategies, including the hepatitis B vaccine program for newborns (HepB), with a strong emphasis on timely administration of the birth dose and completion of the three-dose schedule, have significantly reduced mother-to-child transmission and early childhood HBV infections. With the significant reduction in the cost of antiviral drugs, treatment accessibility and affordability have greatly improved. From July 20 to 21, the "2024 World Hepatitis Day Campaign and Hepatitis Elimination Action Conference" was held in Beijing. Dr. Jidong Jia from Beijing Friendship Hospital ,Capital Medical University delivered a keynote speech titled "Progress and Challenges in the Prevention and Treatment of Hepatitis B in China," where he systematically explained the progress made, the challenges faced, and the urgent actions needed in the prevention and treatment of hepatitis B in China.